May 15, 2019 Comments (0) Blog, Current Investigations

TG Therapeutics – Securities Investigation

TG Therapeutics Investigation, Featured by Top Securities Fraud Attorneys, The White Law Group

TG Therapeutics (fka Manhattan Pharmaceuticals) – National Securities Corp.

Did you lose money investing in TG Therapeutics with National Securities Corporation? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Arbitration claim.

TG Therapeutics, Inc. (Nasdaq:TGTX) is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other therapeutic needs.

Unfortunately for investors, in September 2018 the company’s share price declined 44% after disappointing results in the company’s Unity-CLL trial.  According to reports, the problem stems from Unity-CLL’s inability to show an improvement in overall response among chronic lymphocytic leukaemia (CLL) patients given TG’s combo at interim review. This was the result that TG had instructed the markets to look for, saying a positive result might have served as the basis for immediate US accelerated approval filing.

According to Yahoo finance, the company’s share price was down a total of 57%, against a market gain of about 3.5%, as of March 2019 for the prior 12 months period. Further, current revenues were reportedly just $152,000 for the same time period.

In July 2013, the company reportedly announced the pricing of an underwritten public offering of 5,700,000 shares of its common stock at a price of $6.15 per share. According to a press announcement, National Securities Corporation acted as co-manager in the offering.

The company also filed a Form D to raise capital from investors in 2012. According to the Form D, National Securities Corp. was the associated broker-dealer on the offering as well.

Investigating Potential Claims

The White Law Group is investigating the liability that National Securities Corp. may have for improperly recommending TG Therapeutics to investors.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If you have concerns regarding your investment in TG Therapeutics and would like to speak with a securities attorney about your options, please call The White Law Group at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

Click here for your FREE consultation.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.